Article Versions Notes

Gonzalez-Alvarez I, Bermejo M, Tsume Y, Ruiz-Picazo A, Gonzalez-Alvarez M, Hens B, Garcia-Arieta A, Amidon GE, Amidon GL. An In Vivo Predictive Dissolution Methodology (iPD Methodology) with a BCS Class IIb Drug Can Predict the In Vivo Bioequivalence Results: Etoricoxib Products. Pharmaceutics. 2021; 13(4):507. https://doi.org/10.3390/pharmaceutics13040507

Gonzalez-Alvarez, Isabel, Marival Bermejo, Yasuhiro Tsume, Alejandro Ruiz-Picazo, Marta Gonzalez-Alvarez, Bart Hens, Alfredo Garcia-Arieta, Greg E. Amidon, and Gordon L. Amidon. 2021. "An In Vivo Predictive Dissolution Methodology (iPD Methodology) with a BCS Class IIb Drug Can Predict the In Vivo Bioequivalence Results: Etoricoxib Products" Pharmaceutics 13, no. 4: 507. https://doi.org/10.3390/pharmaceutics13040507

Gonzalez-Alvarez, I., Bermejo, M., Tsume, Y., Ruiz-Picazo, A., Gonzalez-Alvarez, M., Hens, B., Garcia-Arieta, A., Amidon, G. E., & Amidon, G. L. (2021). An In Vivo Predictive Dissolution Methodology (iPD Methodology) with a BCS Class IIb Drug Can Predict the In Vivo Bioequivalence Results: Etoricoxib Products. Pharmaceutics, 13(4), 507. https://doi.org/10.3390/pharmaceutics13040507